12:00 AM
 | 
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iluvien regulatory update

Alimera said in its 2Q12 earnings that it plans to resubmit an NDA to FDA for diabetic macular edema (DME) drug Iluvien fluocinolone acetonide intravitreal implant using available data from the Phase III FAME trials instead of conducting 2 additional clinical trials requested...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >